Table 3.

Ongoing studies on stage III lung cancer incorporating targeted therapies.

NCT identifier	Status	Study title	Intervention	Phase
NCT01857271	Recruiting	Erlotinib hydrochloride before surgery in treating patients with Stage III non-small cell lung cancer (NSCLC) (EVENT)	Drug: Erlotinib hydrochloride	2
			Procedure: therapeutic conventional surgery
			Other: laboratory biomarker analysis
NCT02201992	Recruiting	Crizotinib in treating patients with Stage IB-IIIA NSCLC that has been removed by surgery and ALK fusion mutations (an ALCHEMIST treatment trial)	Drug: Crizotinib	3
			Other: laboratory biomarker analysis
			Other: Placebo
NCT02347839	Recruiting	NEoadjuvant Gefitinib followed by surgery and gefiTinib In unresectAble sTage III NSCLC with epidermal growth factor receptor mutations (NEGOTIATE)	Gefitinib-surgery-gefitinib	2